256 related articles for article (PubMed ID: 28884856)
1. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
Nakase H; Motoya S; Matsumoto T; Watanabe K; Hisamatsu T; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
Aliment Pharmacol Ther; 2017 Nov; 46(9):873-882. PubMed ID: 28884856
[TBL] [Abstract][Full Text] [Related]
2. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
Assa A; Matar M; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Shamir R
Gastroenterology; 2019 Oct; 157(4):985-996.e2. PubMed ID: 31194979
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease.
Mazor Y; Almog R; Kopylov U; Ben Hur D; Blatt A; Dahan A; Waterman M; Ben-Horin S; Chowers Y
Aliment Pharmacol Ther; 2014 Sep; 40(6):620-8. PubMed ID: 25039584
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
Imaeda H; Takahashi K; Fujimoto T; Bamba S; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Selvaraj F; Princen F; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Gearry RB; Selby W; Bell SJ; Brown SJ; Connell WR
J Crohns Colitis; 2018 May; 12(6):653-661. PubMed ID: 29385469
[TBL] [Abstract][Full Text] [Related]
7. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.
Zittan E; Kabakchiev B; Milgrom R; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
J Crohns Colitis; 2016 May; 10(5):510-5. PubMed ID: 26783345
[TBL] [Abstract][Full Text] [Related]
8. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
[TBL] [Abstract][Full Text] [Related]
9. Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study.
Ungar B; Engel T; Yablecovitch D; Lahat A; Lang A; Avidan B; Har-Noy O; Carter D; Levhar N; Selinger L; Neuman S; Natour OH; Yavzori M; Fudim E; Picard O; Kopylov U; Chowers Y; Naftali T; Broide E; Shachar E; Eliakim R; Ben-Horin S
Am J Gastroenterol; 2018 Jun; 113(6):890-898. PubMed ID: 29867175
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.
Vande Casteele N; Baert F; Bian S; Dreesen E; Compernolle G; Van Assche G; Ferrante M; Vermeire S; Gils A
J Crohns Colitis; 2019 Sep; 13(10):1248-1256. PubMed ID: 30820530
[TBL] [Abstract][Full Text] [Related]
11. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.
Verstockt B; Moors G; Bian S; Van Stappen T; Van Assche G; Vermeire S; Gils A; Ferrante M
Aliment Pharmacol Ther; 2018 Oct; 48(7):731-739. PubMed ID: 30109889
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease.
Kato M; Sugimoto K; Ikeya K; Takano R; Matsuura A; Miyazu T; Ishida N; Tamura S; Tani S; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Furuta T; Hanai H
PLoS One; 2021; 16(7):e0254548. PubMed ID: 34242369
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
Bond A; Asher R; Jackson R; Sager K; Martin K; Kneebone A; Philips S; Taylor W; Subramanian S
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):271-6. PubMed ID: 26657455
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease.
Watanabe K; Matsumoto T; Hisamatsu T; Nakase H; Motoya S; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):542-549.e1. PubMed ID: 29104132
[TBL] [Abstract][Full Text] [Related]
16. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease.
Bodini G; Giannini EG; Furnari M; Marabotto E; Baldissarro I; Del Nero L; Assandri L; Moscatelli A; Savarino V; Savarino E
J Gastrointestin Liver Dis; 2015 Dec; 24(4):451-6. PubMed ID: 26697571
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring Serum Drug Levels and Antidrug Antibodies.
Cordero-Coma M; Calleja-Antolín S; Garzo-García I; Nuñez-Garnés AM; Álvarez-Castro C; Franco-Benito M; Ruiz de Morales JG
Ophthalmology; 2016 Dec; 123(12):2618-2625. PubMed ID: 27692527
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study.
Sharma S; Eckert D; Hyams JS; Mensing S; Thakkar RB; Robinson AM; Rosh JR; Ruemmele FM; Awni WM
Inflamm Bowel Dis; 2015 Apr; 21(4):783-92. PubMed ID: 25723614
[TBL] [Abstract][Full Text] [Related]
20. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.
Ungar B; Kopylov U; Engel T; Yavzori M; Fudim E; Picard O; Lang A; Williet N; Paul S; Chowers Y; Bar-Gil Shitrit A; Eliakim R; Ben-Horin S; Roblin X
Aliment Pharmacol Ther; 2017 Jan; 45(2):276-282. PubMed ID: 27862102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
